Monday, October 2, 2023
Monday, October 2, 2023

Contact: 561.316.3330

Medtecs & TSMC Charity Foundation to Donate PPE to Taiwan’s 3 allies in Africa & the Americas

On February 20, 2021, in conjunction with Taiwan’s Ministry of Foreign Affairs, Medtecs Group, a leading personal protective equipment (PPE) supplier headquartered in Taiwan, donated coveralls, isolation gowns and other COVID-19-related PPE to the Kingdom of Eswatini, the Republic of Somaliland and the Commonwealth of Saint Lucia in partnership with TSMC Charity Foundation. The donation was designed to help the Taiwan government fulfill its Taiwan Can Help pledge.

Given Taiwan’s outstanding performance in containing COVID-19 and the relatively abundant supply of protective equipment and clothing locally, Medtecs decided to join forces with the TSMC Charity Foundation to support the Taiwan Can Help diplomatic initiative in conjunction with Taiwan’s Ministry of Foreign Affairs by identifying and assisting countries that were in need of PPE. The donation comprised 150,000 surgical masks, 7,000 coveralls, 11,000 isolation gowns, 6,000 caps, 6,000 sets of shoe covers and 1,500 CoverU Jackes (flight suits). The items will be distributed across the three countries, all of which are struggling to cope with the COVID-19 crisis. TSMC Charity Foundation had generously paid for the shipping costs of the donated goods.

“Medtecs has been the leading partner and prime vendor for Taiwan government’s national stockpiles of strategic goods, including PPE, for more than 10 years, and we are honored to be given the opportunity to join in the government’s efforts to help combat COVID-19 worldwide,” said Medtecs CEO William Yang. “Medtecs has long dedicated itself to creating value not just for our shareholders but for communities where we have operations and offices. Now we’re taking a step further and expanding our humanitarian reach by working side-by-side with the Ministry of Foreign Affairs and the TSMC Charity Foundation to coordinate and sponsor the donation of Medtecs’s safety products and protective clothing at an international level. In particular, we would like to thank Chairperson of the Foundation, Ms Sophie Chang, for her advice and for sharing her experiences in corporate philanthropy.”

Medtecs has always been at the forefront of the fight against viral outbreaks, be it SARS (2003), H1N1 (2009) or Ebola (2014). Ever since the onset of the COVID-19 pandemic in early 2020, the Group has mobilized its resources and distribution centers around the world to provide much needed PPE to over 30 countries, including United States, Germany, Italy, Cambodia, Taiwan and the Philippines, to just name a few. To date, Medtecs has donated over 5 million medical-grade face masks as well as more than 30,000 isolation gowns, and 20,000 coveralls, among other health products, to under-resourced communities and regions worldwide.

This round of donations to the Kingdom of Eswatini, the Republic of Somaliland and the Commonwealth of Saint Lucia is but another example of  Medtecs’s commitment to safeguarding the health and safety of humanity by providing effective and comfortable protective clothing and equipment through a resilient supply chain.

“With uncertainty surrounding the vaccine roll-out in different parts of the world, high-quality, top performing PPE remains the most direct and effective tool for minimizing the risk of infection and controlling the pandemic,” added Mr. Yang.

Medical Device News Magazine
Our publication is dedicated to bringing our readers the latest medical device news. We are proud to boast that our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall purpose and objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Ariceum Therapeutics’ Targeted Radiopharmaceutical 177Lu-satoreotide Exhibits Promising Clinical Response and Good Tolerability Profile in Patients with Advanced Neuroendocrine Tumours

Satoreotide combines Ariceum’s proprietary peptide satoreotide - a first-in-class and best-in-class antagonist of the somatostatin receptor 2 (SSTR2) - with the radioactive isotope ‘payload’ 177Lutetium. SSTR2 is a cell surface protein often overexpressed in certain cancers, including NETs and small cell lung cancer (SCLC).

New Hot Start Isothermal Mixes Boost Sensitivity, Specificity, and Speed of DNA Target Detection

Isothermal mixes are important in a range of isothermal amplification applications, including whole genome amplification, point-of-care assay development and testing, and strand displacement amplification for synthetic biology. However, a common issue with isothermal mixes is non-specific amplification — where primers bind to unintended DNA targets — because amplification often takes place at a fixed temperature which may favour non-specific primer interactions, contrary to PCR. Isothermal mixes can also lead to primer dimer formation, where primers associate with each other and are extended by the polymerase.

Branded Legacy Invests Heavily in Innovation and Growth with $540,000 Expansion

This strategic initiative underscores Branded Legacy's unwavering commitment to innovation, quality, and customer satisfaction. The expansion project is set to infuse over $500,000 worth of inventory into the company, reinforcing its position as a leader in the market.

Cue Biopharma Completes Patient Enrollment in Ph1b Head & Neck Cancer Trial

“Completing the enrollment of the recommended phase 2 dose patient expansion cohort is an important milestone as the data from this trial guides further development plans and associated discussions with the Food and Drug Administration (FDA),” said Daniel Passeri, chief executive officer of Cue Biopharma.

Revvity Expands Access to Base Editing Technology with Aim to Accelerate Discovery to Cure

Michelle Fraser, head of cell and gene therapy at Revvity, underscores the importance of providing broad access to this technology: "Base editing has been extensively demonstrated in numerous studies to safely and precisely control the correction of single base changes at multiple target sites, simultaneously. This streamlined approach simplifies complex multi-gene editing, holding great promise for the development of new cell therapies targeting rare inherited genetic diseases, cancer, and in the creation of universal donor cells as the foundation of allogeneic cell therapies."

By using this website you agree to accept Medical Device News Magazine Privacy Policy